GO:1902034 negative regulation of hematopoietic stem cell proliferation: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902034 describes any process that stops, prevents, or reduces the frequency, rate, or extent of hematopoietic stem cell (HSC) proliferation.
• Negative regulation of HSC proliferation is essential for maintaining HSC quiescence, preventing exhaustion, and preserving lifelong hematopoiesis.
• Key negative regulators include METTL14, GPRASP proteins, Latexin, Spred1, Geminin, Runx2, and vWF, which act through diverse mechanisms such as m6A modification, protein degradation, and signaling inhibition.
• Dysregulation of this process contributes to leukemia, bone marrow failure, and clonal hematopoiesis, with KMT2A::AFF1 fusions and Tet2 mutations driving pre-leukemic states.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise interrogation of negative regulators in HSCs.
• Understanding GO:1902034 provides a foundation for developing therapies that target HSC proliferation in hematological malignancies and regenerative medicine.
Description
Hematopoietic stem cells (HSCs) are a rare population of multipotent cells responsible for the lifelong production of all blood lineages. Their proliferation must be tightly controlled to balance self-renewal with differentiation and to avoid exhaustion or malignant transformation. The Gene Ontology term GO:1902034, negative regulation of hematopoietic stem cell proliferation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of HSC proliferation. This regulatory process is critical for maintaining HSC quiescence, a state essential for long-term repopulating capacity and stress response. Researchers studying HSC biology rely on this term to annotate genes and pathways that restrain HSC cycling, including those involved in mRNA modification, ubiquitin-mediated degradation, and signaling inhibition. Dysregulation of these negative regulators can lead to hematopoietic malignancies, bone marrow failure, and clonal hematopoiesis. Thus, understanding the molecular players and mechanisms underlying GO:1902034 is fundamental for both basic stem cell biology and translational hematology.
negative regulation of hematopoietic stem cell proliferation At A Glance
| GO ID | GO:1902034 |
|---|---|
| GO term | negative regulation of hematopoietic stem cell proliferation |
| Ontology | biological_process |
| Synonym | inhibition of hematopoietic stem cell proliferation; downregulation of hematopoietic stem cell proliferation; negative regulation of hemopoietic stem cell proliferation |
| Major function | Maintains HSC quiescence, prevents HSC exhaustion, and balances self-renewal with differentiation |
| Related processes | Regulation of cell cycle, stem cell homeostasis, hematopoietic stem cell differentiation |
| Key regulators | METTL14, GPRASP1/2, Latexin, Spred1, Geminin, Runx2, vWF |
| Disease relevance | Leukemia, bone marrow failure, clonal hematopoiesis |
What Is GO:1902034?
GO:1902034 is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of hematopoietic stem cell proliferation. It includes mechanisms that maintain HSCs in a quiescent state, inhibit their entry into the cell cycle, or slow their division. This term is a child of negative regulation of cell proliferation and regulation of hematopoietic stem cell proliferation, and it is specific to hematopoietic stem cells, distinguishing it from negative regulation of proliferation in other cell types.
Why Is negative regulation of hematopoietic stem cell proliferation Important in Cell Biology?
Negative regulation of HSC proliferation is vital for preserving the regenerative capacity of the hematopoietic system throughout life. Without proper restraint, HSCs may become exhausted or undergo malignant transformation. This process ensures that HSCs remain quiescent in the bone marrow niche, protecting them from genotoxic stress and maintaining a reservoir for emergency hematopoiesis. Moreover, many leukemia-associated mutations, such as KMT2A::AFF1 fusions and Tet2 mutations, disrupt this regulation, leading to pre-leukemic states and overt leukemia. Therefore, understanding GO:1902034 is essential for developing strategies to manipulate HSC proliferation in regenerative medicine, bone marrow transplantation, and cancer therapy.
• Maintains HSC quiescence and prevents stem cell exhaustion.
• Preserves long-term repopulating capacity and hematopoietic homeostasis.
• Protects HSCs from genotoxic stress and accumulation of DNA damage.
• Dysregulation leads to hematological malignancies such as leukemia.
• Involved in clonal hematopoiesis and age-related hematopoietic decline.
• Critical for successful bone marrow transplantation and engraftment.
• Provides targets for therapeutic intervention in blood cancers.
• Informs strategies for ex vivo HSC expansion for gene therapy.
• Links mRNA modification, ubiquitination, and signaling pathways to stem cell fate.
• Serves as a model for understanding stem cell proliferation control in other tissues.
What Happens During negative regulation of hematopoietic stem cell proliferation?
Maintenance of HSC Quiescence
In simple terms: HSCs are kept in a dormant state to save them for later.
A key mechanism of negative regulation is the maintenance of HSCs in the G0 phase of the cell cycle. This quiescence is actively enforced by transcription factors and signaling pathways that suppress cell cycle entry. For example, Spred1, a negative regulator of the Ras/MAPK pathway, helps maintain HSC quiescence and prevents exhaustion under stress conditions. Similarly, Geminin, a protein that inhibits DNA replication licensing, plays a role in cell fate determination by keeping HSCs quiescent. Disruption of these regulators leads to increased HSC proliferation and eventual depletion of the stem cell pool.
Inhibition of Proliferative Signaling
In simple terms: Signals that tell HSCs to divide are blocked.
Negative regulation often involves the inhibition of mitogenic signaling pathways. GPRASP proteins, for instance, are critical negative regulators of HSC transplantation and proliferation, likely by modulating G protein-coupled receptor signaling. Latexin, a carboxypeptidase inhibitor, has been shown to negatively regulate HSC proliferation and is associated with HSC frequency. These proteins act as brakes on signaling cascades that would otherwise promote cell cycle progression.
Epigenetic and Post-Transcriptional Control
In simple terms: Chemical marks on RNA and DNA can slow down HSC division.
Epigenetic modifications and RNA processing are emerging as important mechanisms. METTL14, a component of the m6A RNA methyltransferase complex, inhibits HSC/progenitor differentiation and promotes leukemogenesis, but its role in proliferation is context-dependent; loss of METTL14 leads to increased HSC proliferation and impaired reconstitution. This highlights how m6A modification can negatively regulate HSC proliferation. Additionally, Runx2 was identified in a genome-wide screen as a novel regulator of HSC expansion, acting to restrict HSC proliferation and T-cell commitment.
Protein Degradation and Turnover
In simple terms: Destruction of specific proteins stops HSCs from dividing.
Ubiquitin-proteasome-mediated degradation of cell cycle regulators is another layer of control. For example, vWF was recently identified as a negative regulator of Tet2 mutant HSC expansion, suggesting that extracellular matrix proteins can influence HSC proliferation through proteostasis. The precise mechanisms by which these proteins are targeted for degradation and how they impact HSC cycling are active areas of research.
Integration with Differentiation Cues
In simple terms: Stopping division is linked to deciding what blood cell type to become.
Negative regulation of HSC proliferation is often coupled with differentiation. For instance, KMT2A::AFF1 fusions drive a pre-leukemic state by altering the balance between self-renewal and differentiation, in part by dysregulating proliferation-associated genes. Thus, the decision to divide or not is intimately tied to lineage commitment, ensuring that HSCs do not proliferate uncontrollably while differentiating.
Key Genes Involved in GO:1902034 negative regulation of hematopoietic stem cell proliferation
The following genes and proteins have been experimentally implicated in the negative regulation of hematopoietic stem cell proliferation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL14 | m6A RNA methyltransferase; inhibits HSC/progenitor differentiation | Loss leads to increased HSC proliferation and leukemogenesis |
| GPRASP1/2 | Negative regulator of HSC transplantation and proliferation | Critical for HSC engraftment; potential target for expansion |
| Latexin | Carboxypeptidase inhibitor; negative regulator of HSC proliferation | Associated with HSC frequency and quiescence |
| Spred1 | Inhibitor of Ras/MAPK signaling; maintains HSC quiescence | Prevents HSC exhaustion under stress |
| Geminin | Inhibits DNA replication licensing; regulates cell fate | Role in HSC quiescence and differentiation |
| Runx2 | Transcription factor; restricts HSC expansion and T-cell commitment | Identified in genome-wide screen as novel regulator |
| vWF | Extracellular matrix protein; negative regulator of Tet2 mutant HSC expansion | Potential therapeutic target in clonal hematopoiesis |
| KMT2A::AFF1 | Fusion oncogene; drives pre-leukemic state | Dysregulates HSC proliferation and differentiation |
| Tet2 | DNA demethylase; mutations lead to clonal expansion | Loss enhances HSC proliferation; vWF counteracts |
| CD24 | Cell surface marker; associated with pre-leukemic state | Marker of KMT2A::AFF1-driven pre-leukemia |
| AFF1 | Partner in KMT2A fusion; involved in transcriptional elongation | Oncogenic fusion with KMT2A |
| KMT2A | Histone methyltransferase; involved in gene regulation | Fusion with AFF1 alters HSC proliferation |
| Ras | Small GTPase; promotes proliferation | Spred1 inhibits Ras to maintain quiescence |
| MAPK | Kinase cascade; promotes proliferation | Spred1 negatively regulates MAPK |
| m6A | RNA modification; affects mRNA stability and translation | METTL14 deposits m6A to regulate HSC proliferation |
| GPRASP | G protein-coupled receptor associated sorting proteins | Negative regulators of HSC transplantation |
| Latexin | Endogenous inhibitor of carboxypeptidases | Regulates HSC proliferation |
How Is negative regulation of hematopoietic stem cell proliferation Regulated?
The negative regulation of HSC proliferation is itself subject to regulation by various intrinsic and extrinsic factors. Intracellularly, the Ras/MAPK pathway is a key target; Spred1 acts as a negative feedback regulator of this pathway to maintain HSC quiescence. Epigenetic modifiers such as METTL14 modulate m6A levels on mRNAs encoding proliferation-related genes, thereby influencing HSC cycling. Extracellular cues from the bone marrow niche, including cytokines and cell-cell interactions, also impact HSC proliferation. For example, GPRASP proteins may modulate signaling from G protein-coupled receptors. Additionally, the transcription factor Runx2 restricts HSC expansion, and its expression is dynamically regulated during stress hematopoiesis. Understanding how these regulators are themselves controlled is crucial for manipulating HSC proliferation for therapeutic purposes.
negative regulation of hematopoietic stem cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KMT2A::AFF1 | Pre-leukemic state, acute lymphoblastic leukemia | Knock-in of fusion gene in human HSPCs; CD24+ pre-leukemic model |
| METTL14 | Leukemogenesis, myelodysplastic syndrome | Knockout in mouse HSCs; m6A profiling |
| Tet2 | Clonal hematopoiesis, myeloid malignancies | Knockout mouse model; vWF overexpression |
| Spred1 | HSC exhaustion, bone marrow failure | Knockout mouse; stress hematopoiesis assays |
| GPRASP1/2 | HSC transplantation failure | Knockout mouse; transplantation assays |
Leukemia and Pre-leukemic States
Dysregulation of negative regulators of HSC proliferation is a hallmark of leukemia. KMT2A::AFF1 fusions drive an ontogeny-specific pre-leukemic state characterized by increased HSC proliferation and blocked differentiation, leading to acute lymphoblastic leukemia. Loss of METTL14, which normally inhibits HSC/progenitor differentiation, promotes leukemogenesis by enhancing HSC proliferation. These findings underscore the importance of GO:1902034 in preventing malignant transformation.
Clonal Hematopoiesis and Aging
Age-related clonal hematopoiesis is often driven by mutations in genes such as Tet2, which confer a proliferative advantage to HSCs. vWF has been identified as a negative regulator of Tet2 mutant HSC expansion, suggesting that the niche can counteract clonal expansion. This highlights how negative regulation of HSC proliferation can be exploited to prevent or treat clonal hematopoiesis.
Bone Marrow Failure and HSC Exhaustion
Inadequate negative regulation can lead to HSC exhaustion, resulting in bone marrow failure. For instance, loss of Spred1 leads to increased HSC proliferation and eventual exhaustion under stress. Similarly, Geminin deficiency affects HSC fate determination and may impair long-term hematopoiesis. Thus, proper negative regulation is essential for maintaining a functional HSC pool.
Therapeutic Implications in Transplantation
Manipulating negative regulators can enhance HSC engraftment. GPRASP proteins are critical negative regulators of HSC transplantation; their inhibition might improve transplant outcomes. Conversely, understanding how to maintain quiescence ex vivo could improve gene therapy protocols. These examples illustrate the translational potential of targeting GO:1902034.
From negative regulation of hematopoietic stem cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase HSC proliferation? | Knockout mouse or human HSC CRISPR KO |
| Does a specific point mutation in a regulator alter HSC quiescence? | Point-mutation knock-in via CRISPR |
| Does overexpression of a negative regulator suppress HSC expansion? | Overexpression lentiviral or knock-in at safe locus |
| How does a fusion oncogene affect HSC proliferation? | Knock-in of KMT2A::AFF1 fusion in human HSPCs |
| What is the role of m6A modification in HSC proliferation? | METTL14 KO and m6A-seq |
| Can a secreted factor inhibit HSC proliferation? | vWF overexpression in Tet2 mutant HSCs |
How to Study the negative regulation of hematopoietic stem cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CFSE dilution | Cell division history | In vitro HSC proliferation |
| EdU incorporation | DNA synthesis (S phase) | Proliferation rate in cultured HSCs |
| Competitive repopulation | HSC self-renewal and engraftment | In vivo functional analysis |
| m6A-seq (MeRIP-seq) | m6A RNA modification sites | METTL14 target identification |
| Low-input proteomics | Protein expression in rare cells | vWF discovery in Tet2 mutant HSCs |
| Single-cell RNA-seq | Transcriptional heterogeneity | HSC quiescence vs activation |
| ChIP-seq | Transcription factor binding | Runx2 target genes in HSCs |
| CRISPR screen | Genome-wide regulators | Identification of novel negative regulators |
In Vitro HSC Proliferation Assays
To study negative regulation of HSC proliferation, researchers commonly use in vitro culture systems with cytokines that support HSC expansion. Proliferation is measured by CFSE dilution, EdU incorporation, or cell counting. These assays can be combined with CRISPR knockout of candidate genes to assess their impact on HSC cycling.
In Vivo Transplantation and Competitive Repopulation
The gold standard for HSC function is transplantation into irradiated recipients. Competitive repopulation assays using congenic markers allow quantification of HSC self-renewal and proliferation. Negative regulators can be tested by overexpressing or knocking out genes in donor HSCs prior to transplantation.
RNA Sequencing and Epigenomic Profiling
Bulk or single-cell RNA-seq can reveal changes in cell cycle gene expression upon perturbation of negative regulators. For m6A-related genes like METTL14, m6A-seq (MeRIP-seq) identifies modified transcripts. ATAC-seq and ChIP-seq can assess chromatin accessibility and transcription factor binding at proliferation loci.
Proteomics and Interaction Studies
Low-input proteomics has been used to identify vWF as a negative regulator of Tet2 mutant HSC expansion. Co-immunoprecipitation and mass spectrometry can uncover protein complexes involving GPRASP, Latexin, and other regulators. These methods help elucidate the molecular mechanisms of negative regulation.
How CRISPR Can Be Used to Study GO:1902034 negative regulation of hematopoietic stem cell proliferation
Knockout
CRISPR knockout is widely used to study negative regulators of HSC proliferation. By disrupting genes such as METTL14, GPRASP1/2, or Spred1 in HSCs, researchers can assess whether loss of function leads to increased proliferation and HSC exhaustion. Genome-wide CRISPR screens have identified Runx2 as a novel regulator of HSC expansion.
Point Mutation
Point mutations can mimic disease-associated variants or disrupt specific functional domains. For example, introducing point mutations in the catalytic domain of METTL14 can separate its m6A methyltransferase activity from its role in HSC proliferation. CRISPR base editing or homology-directed repair (HDR) enables precise point mutations in HSCs.
Knock-in
Knock-in models are essential for studying fusion oncogenes like KMT2A::AFF1, which drive pre-leukemic states. CRISPR-mediated knock-in of the fusion gene into the endogenous locus recapitulates ontogeny-specific effects on HSC proliferation. Tagged knock-in (e.g., GFP or HA) allows tracking of endogenous protein expression and localization.
Overexpression
Overexpression of negative regulators can suppress HSC proliferation and may protect against leukemic transformation. For instance, overexpression of vWF in Tet2 mutant HSCs reduces their expansion. CRISPR activation (CRISPRa) or lentiviral overexpression can be used to achieve sustained expression in HSCs.
How EDITGENE Supports negative regulation of hematopoietic stem cell proliferation Research
Researchers studying negative regulation of hematopoietic stem cell proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining HSC cycling, and to dissect the precise molecular mechanisms. This requires robust, reproducible CRISPR-based models that can be deployed in primary human HSCs or mouse models. EDITGENE provides end-to-end services to accelerate such discoveries.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of hematopoietic stem cell proliferation research.
Frequently Asked Questions About negative regulation of hematopoietic stem cell proliferation
What is negative regulation of hematopoietic stem cell proliferation?
It is the biological process that stops or reduces the frequency, rate, or extent of hematopoietic stem cell proliferation, as defined by GO:1902034.
What genes are involved in negative regulation of hematopoietic stem cell proliferation?
Key genes include METTL14, GPRASP1/2, Latexin, Spred1, Geminin, Runx2, and vWF, among others.
Why is negative regulation of HSC proliferation important?
It maintains HSC quiescence, prevents exhaustion, and protects against leukemia and bone marrow failure.
What diseases are associated with dysregulated HSC proliferation?
Leukemia, clonal hematopoiesis, bone marrow failure, and myelodysplastic syndromes.
How can I study negative regulators of HSC proliferation?
Use CRISPR knockout, point mutation, knock-in, or overexpression models combined with in vitro proliferation assays and in vivo transplantation.
What is the role of METTL14 in HSC proliferation?
METTL14 inhibits HSC/progenitor differentiation and promotes leukemogenesis; its loss increases HSC proliferation.
How does Spred1 regulate HSC quiescence?
Spred1 inhibits Ras/MAPK signaling to maintain HSC quiescence and prevent exhaustion.
What is the connection between KMT2A::AFF1 and HSC proliferation?
KMT2A::AFF1 fusion drives a pre-leukemic state with increased HSC proliferation and blocked differentiation.
Can vWF suppress HSC expansion?
Yes, vWF has been identified as a negative regulator of Tet2 mutant HSC expansion.
What CRISPR services are available for studying HSC proliferation?
EDITGENE offers knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to HSC research.
Conclusion
GO:1902034, negative regulation of hematopoietic stem cell proliferation, is a fundamental biological process that safeguards HSC function and prevents hematological disease. The diverse mechanisms, from m6A modification to signaling inhibition, highlight the complexity of HSC regulation. Continued research using advanced CRISPR models will uncover new therapeutic targets for leukemia, bone marrow failure, and regenerative medicine.
References
- 1. Meaker GA et al.. 2025. A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.. Blood 146(26):3188-3200 PMID: 40961240
- 2. Calderón AS et al.. 2025. Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state.. Leukemia 39(9):2099-2111 PMID: 40646135
- 3. Weng H et al.. 2018. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.. Cell Stem Cell 22(2):191-205.e9 PMID: 29290617
- 4. Zhang C et al.. 2018. Latexin and hematopoiesis.. Curr Opin Hematol 25(4):266-272 PMID: 29608488
- 5. Tadokoro Y et al.. 2018. [Regulation of hematopoietic stem cell homeostasis by Spred1].. Rinsho Ketsueki 59(11):2441-2448 PMID: 30531141
- 6. Morales-Hernández A et al.. 2020. GPRASP proteins are critical negative regulators of hematopoietic stem cell transplantation.. Blood 135(14):1111-1123 PMID: 32027737
- 7. Jassinskaja M et al.. 2026. Low-input proteomics identifies vWF as a negative regulator of Tet2 mutant hematopoietic stem cell expansion.. Cell Rep 45(1):116770 PMID: 41447537
- 8. Yasunaga S et al.. 2016. Role of Geminin in cell fate determination of hematopoietic stem cells (HSCs).. Int J Hematol 104(3):324-9 PMID: 27422432
